Abstract
Lung, breast, and esophageal cancer represent three common malignancies with high incidence and mortality worldwide. The management of these tumors critically relies on radiotherapy as a major part of multi-modality care, and treatment-related toxicities, such as radiation-induced pneumonitis and/or lung fibrosis, are important dose limiting factors with direct impact on patient outcomes and quality of life. In this review, we summarize the current understanding of radiation-induced pneumonitis and pulmonary fibrosis, present predictive factors as well as recent diagnostic and therapeutic advances. Novel candidates for molecularly targeted approaches to prevent and/or treat radiation-induced pneumonitis and pulmonary fibrosis are discussed.
Original language | English |
---|---|
Article number | 214 |
Number of pages | 16 |
Journal | Radiation Oncology |
Volume | 15 |
Issue number | 1 |
DOIs | |
Publication status | Published - 10 Sept 2020 |
Keywords
- BREAST-CANCER PATIENTS
- CLINICAL-FEATURES
- CONCURRENT CHEMOTHERAPY
- EUROPEAN-ORGANIZATION
- HYPERFRACTIONATED RADIATION
- OBLITERANS ORGANIZING PNEUMONIA
- RISK-FACTORS
- STEM-CELLS
- THORACIC RADIOTHERAPY
- TUMOR VOLUME